Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Very good DD...as usual.
Looks good to me.
Easily referenced presentations..
Haven't had time to go over these yet but they look comprehensive:
https://ir.akebia.com/data-presentations
Historic Short Interest:
You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest
Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch
Settlement Date/Short Interest/Percent Change/Average Daily Share Volume/Days to Cover
12/31/2020 28,675,599 20.84 5,040,993 5.69
12/15/2020 23,730,064 0.79 5,157,773 4.60
11/30/2020 23,543,896 (6.18) 4,207,173 5.60
11/13/2020 25,095,299 (6.10) 5,145,547 4.88
10/30/2020 26,725,097 7.62 10,055,146 2.66
10/15/2020 24,831,748 12.02 6,340,540 3.92
09/30/2020 22,166,741 141.79 8,619,035 2.57
09/15/2020 9,167,693 12.37 15,663,814 1.00
08/31/2020 8,158,475 (10.01) 972,986 8.38
08/14/2020 9,065,803 (5.28) 954,760 9.50
07/31/2020 9,571,518 (1.70) 734,079 13.04
07/15/2020 9,737,356 1.00 1,218,888 7.99
06/30/2020 9,641,252 61.40 1,937,554 4.98
06/15/2020 5,973,562 18.54 1,165,721 5.12
05/29/2020 5,039,409 (21.29) 1,014,751 4.97
05/15/2020 6,402,203 (16.02) 3,532,134 1.81
04/30/2020 7,623,059 3.81 746,700 10.21
04/15/2020 7,343,578 8.37 890,711 8.24
03/31/2020 6,776,645 (6.55) 1,423,097 4.76
03/13/2020 7,251,762 (2.38) 1,737,624 4.17
02/28/2020 7,428,762 (5.55) 1,760,016 4.22
02/14/2020 7,865,192 (9.56) 1,168,402 6.73
01/31/2020 8,696,150 (6.94) 1,279,885 6.79
01/15/2020 9,344,280 (5.07) 896,753 10.42
File Date Form Security Prev
Shares Current
Shares Change
(Percent) Ownership
(Percent) Change
(Percent)
2020-11-10 13G WELLINGTON MANAGEMENT GROUP LLP 17,698,113 12.35
2020-10-13 13G/A STATE STREET CORP 15,340,471 10.70
2020-10-09 13G/A BAUPOST GROUP LLC/MA 0 0.00
2020-02-13 13G Nantahala Capital Management, LLC 6,737,120 5.70
2020-02-05 13G/A BlackRock Inc. 10,261,147 8.60
2019-02-14 13G/A ABRAMS CAPITAL MANAGEMENT, L.P.
2019-01-11 13D/A Satter Muneer A 3,067,043 2.60
2019-01-07 13G/A Novo Holdings A/S 3,100,000
File Date Form Investor Opt Avg Share Price Shares Shares Changed
(%) Value
($1000) Value Changed
(%) Cost Basis
(x1000) Profit
(x1000) Return
(%)
2020-11-10 13F State Street Corp 8.04 15,340,471 206.07 38,505 -43.43
2020-11-27 NP XBI - SPDR(R) S&P(R) Biotech ETF 12,615,105 31,664
2020-11-06 13F BlackRock Inc. 8.05 11,744,162 3.35 29,480 -80.90
2020-11-16 13F Wellington Management Group Llp 8.04 7,924,972 8.94 19,892 -79.86
2020-11-16 13F Avidity Partners Management LP 7,324,000 18,383
2020-11-16 13F Vanguard Group Inc 8.04 6,565,065 -10.32 16,478 -83.43
2020-11-16 13F Nantahala Capital Management, LLC 8.04 5,746,623 -5.81 14,424 -82.59
2020-11-13 13F Abrams Capital Management, L.p. 8.04 5,656,462 0.00 14,198 -81.52
2020-11-16 13F Woodline Partners LP 8.05 5,458,936 747.36 13,702 56.61
2020-11-27 NP VTSMX - Vanguard Total Stock Market Index Fund Investor Shares 3,310,423 8,309
2020-11-25 NP IWM - iShares Russell 2000 ETF 2,912,340 7,310
2020-12-29 NP VEXPX - VANGUARD EXPLORER FUND Investor Shares 2,706,816 6,009
Yes, should continue to go up. They will file for approval within weeks which will be another boost.
Holy shit. Theres no reason why we should be bag holding right now... this is so undervalued.
$90-$100M ? Based off previous quarters. Let see what happens.
Do we have any ideas on earnings??
I’ve think we’ve hit the lowest of the lows. Hopefully it starts to climb back up.
* * $AKBA Video Chart 10-27-2020 * *
Link to Video - click here to watch the technical chart video
I don't think anything is wrong except weak demand due to market selloff.
Also have to remember now the company has to send data to FDA to get
and answer which will be next year. A lot of people dont want to wait that long for results.
I don't understand it at all. It looks like highly illegal manipulation. Feel bad for all the bag holders as this was a good play.
Management really f'd this up by not closely scrutinizing their own data the first time they released the results, but that may have been intentional on their end.
Either way, something very "wrong" is happening here.
Well. I'm bag holding. Good news out. HC wainwright Price target $9 and its still heading south. Huge 20m share traded day that it ran up $4 from mark in May and shortly after with that volume. Earnings coming and expected to be low. Hoping they beat estimates to be able to recover some loss. Something odd with this.
* * $AKBA Video Chart 10-23-2020 * *
Link to Video - click here to watch the technical chart video
This is seriously disheartening. 33% drop in 3 days. Followed by almost 4x the number of shares traded daily today alone and its on ly back up 5%.
Really dont like Market Maker Moves.....
Volume needs to be around or close to 22 million. Thats how much the shorts and/or sales increased when they brought it down. It was over a dollar down pushed. Like I said that crap should be illegal. The average price from analysts is like $8.7 There is no need to keep it at or near the lowest valuation if there is bid support.
What the hell just happened? I was thinking about dumping earlier, but after I came back from my walk, AKBA shot up???
Debating on selling. Market makers dumped their loads off that they stole. Afternoon rally doesnt keep it over 4 im out.
Whatcha thinking???
U holding over weekend??
Yeah I held. What a crazy day. Appreciate ur input.. I want to to see a really good run!!!
Now we know why they did a stop loss raid. Excellent news out. hold on tight. Still should be illegal for market makers to do that. Alot of people that got stopped out will be pissed
Filed FINRA complaint. Oh well let's see where this goes. Holding until Monday at least.
APPROX 38 Market makers and or brokers listed on level 2. This is retarded. Average is 14. This stock has alot of attention for such a drop happening.
Not strange movement at all.
They got squeezed. Market Makers need to have a "stock pile" of shares and are allowed to move stock price. This is to "provide a stable market". Its earnings season. So you would think the right thing to do if they got caught and were coming up short then they should move the price up to a point where "retail" wants to sell....
Nah Market Makers move it down for what ever BS reason until "retail" sells for a loss. "See its not deemed valuable enough to hold". If no one panic sells or sells then they can't build their position to provide so it has to be brought up because its in investors hands not day traders. This should be illegal but its not. once they have enough or bring it down enough the BS stops. Problem is no ones going to hold for that big of a loss to wait for the return. They'll get out until "bottom is in" then buy back in if they like the company.
Either ride the dip or increase position when they are done by buying back in. Problem is "when are they done?" once they are they with let it go right back up quick.
They aren't supposed to undercut retail ask price either but I watch it happen all the time. No one seems to take the time to take screen shots and report it. Only a slap on the wrist to them anyway. all those T trades that undercut retail ask price.....
Strange movement
Found it weird that this was doing really well this morning, then dropped for some reason
Who in the heck authorizes MM move plus or minus 1.50 on a 3.8cent stock? MM MOVE +-1.50 JUST SHOWED UP ON TD AMERITRADE APP. They need shares. trying to get that stop loss raid in. Something huge....I mean huge is coming.
What changed? You might ask.
"Akebia reported positive top-line results from INNO2VATE demonstrating that vadadustat achieved the program's primary and key secondary efficacy endpoints and also achieved the primary safety endpoint." Yeah safety endpoint met.
Data is incoming in case people are wondering why its grinding up. Panic sell off recently? whoops. Our gain their loss.
https://www.otcmarkets.com/stock/AKBA/news/story?e&id=1711639
Just shows a new investment group bought in. Means it has Eyes on to me. Nothing "ground breaking" per say.
The filing backs up the articles from 2 weeks ago saying hedge funds and investors are bullish on $AKBA.
Waiting to see more filings for the "reported" 6 others that jumped in too.
This SC 13G/A on the 13th almost cancels out the SC 13G/A from the 9th. So the sell off from the filing on the 9th should reverse.
Appears to be a resistance of around 3.60, we break that and stay we should be good to go lol.
https://finance.yahoo.com/news/hedge-funds-never-bullish-akebia-212747639.html
When do the 10,000,000 shares affect the price?? Are we just waiting??
$AKBA
State Street Global Advisors (SSGA) is the asset management division of State Street Corporation and the world's third largest asset manager,with nearly $3.05 trillion (USD)in assets under management as of 30 June 2020
https://www.otcmarkets.com/filing/html?id=14439174&guid=QsweUeDrQVuuLth
Fibonacci 32 $5.10 , Fibonacci 68 $7.664 , gap filling $10.26, approval "overshooting top" $20 !!!
Global Phase 3 Clinical Trials of Vadadustat vs. Darbepoetin Alfa for Treatment of Anemia in Patients with Dialysis-Dependent CKD
BACKGROUND
Vadadustat (VADA) is an investigational, oral, hypoxia-inducible factor prolyl hydroxylase inhibitor that has advanced to phase 3 development for treatment of anemia of CKD. In phase 2 trials, VADA raised and maintained Hb concentrations.
METHODS
Two randomized, phase 3, global, open-label, sponsor-blind, parallel-group active-controlled noninferiority (NI) trials comparing VADA vs darbepoetin alfa (DA) were conducted in patients with anemia of DD-CKD (INNO2VATE trials). The trials included 1) Correction/Conversion trial of patients new to dialysis (incident trial, NCT02865850) and 2) Conversion trial of patients on maintenance dialysis (prevalent trial, NCT02892149). The primary safety endpoint was time to first major adverse cardiovascular event (MACE: all-cause mortality, nonfatal MI, nonfatal stroke) prespecified as a pooled analysis of both trials. Primary and key secondary efficacy endpoints, prespecified as separate analyses for each trial, were mean difference in change in Hb from baseline between VADA vs DA to wks 24-36 and wks 40-52, respectively.
RESULTS
3923 patients were randomized 1:1 to VADA or DA (incident, N=369; prevalent, N=3554). Median (Q1, Q3) duration of follow-up was 1.2 (0.8, 1.7) and 1.7 (1.2, 2.2) years in the incident and prevalent trials, respectively. VADA was noninferior to DA for time to first MACE (HR 0.96; 95% CI: 0.83, 1.11) and met a prespecified NI margin of 1.25. Among incident dialysis patients, the least squares (LS) mean difference in change in Hb between VADA vs DA from baseline to wks 24-36 was -0.31 g/dL (95% CI: -0.53, -0.10) and from wks 40-52 was -0.07 g/dL (95% CI: -0.34, 0.19). In the prevalent trial, the LS mean difference in change in Hb from baseline to wks 24-36 was -0.17 g/dL (95% CI: -0.23, -0.10), and wks 40-52 was -0.18 g/dL (95% CI: -0.25, -0.12). Primary and key secondary efficacy endpoints met the prespecified NI margin of -0.75 g/dL in both trials. Incidence of treatment-emergent adverse events (TEAEs) in VADA vs DA was 83.8% vs 85.5% in the incident trial and 88.3% vs. 89.3% in the prevalent trial, respectively.
CONCLUSION
VADA was noninferior to DA in time to first MACE and correction/maintenance of Hb in DD-CKD patients with anemia. The incidence of TEAEs was comparable between VADA and DA.
https://www.asn-online.org/education/kidneyweek/2020/program-abstract.aspx?controlId=3441404
* * $AKBA Video Chart 10-12-2020 * *
Link to Video - click here to watch the technical chart video
Would really like to see the morning gap close before end of day.
Really appreciate u and stock market pirate.. exciting.
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
399
|
Created
|
04/17/15
|
Type
|
Free
|
Moderators |
We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat. Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.
VAFSEO® (vadadustat)is approved for use in 34 countries. Vadadustat has not been approved by the U.S. Food & Drug Administration.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |